Should I buy or sell Catalyst Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CPRX shares. View CPRX analyst ratings or view top-rated stocks .

What is Catalyst Pharmaceuticals' stock price target for 2024?

5 Wall Street analysts have issued 12 month price objectives for Catalyst Pharmaceuticals' stock. Their CPRX share price targets range from $23.00 to $34.00. On average, they anticipate the company's share price to reach $26.43 in the next twelve months. This suggests a possible upside of 72.3% from the stock's current price. View analysts price targets for CPRX or view top-rated stocks among Wall Street analysts .

How have CPRX shares performed in 2024?

Catalyst Pharmaceuticals' stock was trading at $16.81 at the start of the year. Since then, CPRX shares have decreased by 8.7% and is now trading at $15.34. View the best growth stocks for 2024 here .

When is Catalyst Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our CPRX earnings forecast .

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) posted its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported $0.49 EPS for the quarter, beating analysts' consensus estimates of $0.45 by $0.04. The biopharmaceutical company earned $110.57 million during the quarter, compared to the consensus estimate of $105.78 million. Catalyst Pharmaceuticals had a net margin of 17.93% and a trailing twelve-month return on equity of 26.56%.

What ETFs hold Catalyst Pharmaceuticals' stock?

ETFs with the largest weight of Catalyst Pharmaceuticals (NASDAQ:CPRX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) , Invesco Biotechnology & Genome ETF (PBE) , Janus Henderson Small Cap Growth Alpha ETF (JSML) , Invesco S&P SmallCap Health Care ETF (PSCH) , ALPS Medical Breakthroughs ETF (SBIO) , ERShares NextGen Entrepreneurs ETF (ERSX) , First Trust Active Factor Small Cap ETF (AFSM) and Hartford Multifactor Small Cap ETF (ROSC) .

What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings?

Catalyst Pharmaceuticals updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $455.0 million-$475.0 million, compared to the consensus revenue estimate of $463.2 million.

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX) , Sorrento Therapeutics (SRNE) , Amarin (AMRN) , Inovio Pharmaceuticals (INO) , Corbus Pharmaceuticals (CRBP) , Micron Technology (MU) , Verastem (VSTM) , Exelixis (EXEL) , Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD) .

Who are Catalyst Pharmaceuticals' major shareholders?

Catalyst Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.12%), Juncture Wealth Strategies LLC (0.08%), Los Angeles Capital Management LLC (0.07%), Toth Financial Advisory Corp (0.03%), Strategic Advocates LLC (0.01%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Alicia Grande , Brian Elsbernd, Carmen Jeffrey Del, David S Tierney, Donald A Denkhaus, Gary Ingenito , Patrick J Mcenany , Philip H Coelho , Preethi Sundaram and Steve Miller . View institutional ownership trends .

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CPRX

Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)

Free CPRX Stock Alerts

$15.34

-0.66 (-4.13%)

(As of 04/18/2024 ET)

Compare

Today's Range: $15.33
▼
$16.25
50-Day Range: $13.18
▼
$17.01
52-Week Range: $11.09
▼
$17.78

Volume: 1.49 million shs
Average Volume: 1.42 million shs
Market Capitalization: $1.81 billion

P/E Ratio: 25.15
Dividend Yield: N/A
Price Target: $26.43

Get Catalyst Pharmaceuticals alerts:

Catalyst Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 72.3% Upside
$26.43 Price Target
Short Interest: Bearish
6.06% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.99
Upright™ Environmental Score
News Sentiment: 1.43
Based on 3 Articles This Week
Insider Trading: Selling Shares
$803,000 Sold Last Quarter
Proj. Earnings Growth: 20.44%
From $1.81 to $2.18 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.99 out of 5 stars

Medical Sector

5th out of 918 stocks

Pharmaceutical Preparations Industry

2nd out of 402 stocks

4.5

Analyst's Opinion

Consensus Rating
Catalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Catalyst Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
6.06% of the float of Catalyst Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Catalyst Pharmaceuticals has a short interest ratio ("days to cover") of 4.1.
Change versus previous month
Short interest in Catalyst Pharmaceuticals has recently increased by 3.77%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Catalyst Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Catalyst Pharmaceuticals does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Catalyst Pharmaceuticals has received a 52.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Amifampridine" and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for Catalyst Pharmaceuticals is -1.99.

3.0

News and Social Media Coverage

News Sentiment
Catalyst Pharmaceuticals has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Catalyst Pharmaceuticals this week, compared to 5 articles on an average week.
Search Interest
Only 9 people have searched for CPRX on MarketBeat in the last 30 days. This is a decrease of -47% compared to the previous 30 days.
MarketBeat Follows
19 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 111% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Catalyst Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $803,000.00 in company stock.
Percentage Held by Insiders
12.10% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
79.22% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

4.4

Earnings and Valuation

Earnings Growth
Earnings for Catalyst Pharmaceuticals are expected to grow by 20.44% in the coming year, from $1.81 to $2.18 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Catalyst Pharmaceuticals is 25.15, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 144.53.
Price to Earnings Ratio vs. Sector
The P/E ratio of Catalyst Pharmaceuticals is 25.15, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 253.15.
Price to Earnings Growth Ratio
Catalyst Pharmaceuticals has a PEG Ratio of 0.86. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Catalyst Pharmaceuticals has a P/B Ratio of 4.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

CPRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CPRX Stock News Headlines

April 11, 2024 | insidertrades.com

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director David S. Tierney Sells 25,000 Shares

March 30, 2024 | insidertrades.com

Brian Elsbernd Sells 25,000 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock

April 19, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

April 12, 2024 | americanbankingnews.com

David S. Tierney Sells 25,000 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock

April 8, 2024 | msn.com

Single Catalyst Paves the Way for Efficient Drug Synthesis

April 7, 2024 | cnn.com

Catalyst Pharmaceuticals, Inc.

April 6, 2024 | seekingalpha.com

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

April 5, 2024 | nasdaq.com

First Week of May 17th Options Trading For Catalyst Pharmaceuticals (CPRX)

April 19, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

March 28, 2024 | finance.yahoo.com

Insider Sell: Chief Compliance/Legal Officer Brian Elsbernd Sells 25,000 Shares of Catalyst ...

March 28, 2024 | globenewswire.com

Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day

March 27, 2024 | markets.businessinsider.com

Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals

March 27, 2024 | globenewswire.com

Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium

March 27, 2024 | investorplace.com

3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List

March 22, 2024 | finance.yahoo.com

Investors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have seen strong returns of 271% over the past three years

March 18, 2024 | investorplace.com

7 Biotech Stocks Ready to Ride the Sector's Resurgence

March 15, 2024 | finance.yahoo.com

CPRX Apr 2024 12.500 call

March 15, 2024 | finance.yahoo.com

CPRX Apr 2024 17.500 put

March 14, 2024 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: REPRO-MED Systems (KRMD), Catalyst Pharma (CPRX)

March 14, 2024 | finance.yahoo.com

CPRX Apr 2024 20.000 put

March 14, 2024 | finanznachrichten.de

Santhera Pharmaceuticals Holding AG: Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States

March 14, 2024 | finance.yahoo.com

Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States

March 14, 2024 | globenewswire.com

Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States

March 13, 2024 | markets.businessinsider.com

Catalyst Pharmaceutical Gains Following US Commercial Launch Of Agamree

March 13, 2024 | globenewswire.com

Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)

March 10, 2024 | investorplace.com

3 Sexy Small-Cap Stocks to Add Sizzle to Your Portfolio

March 5, 2024 | fool.com

3 Biopharma Stocks You Don't Want to Miss in the New Bull Market

See More Headlines

Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CPRX
CUSIP: N/A
CIK: 1369568
Web: www.catalystpharma.com
Phone: (305) 420-3200
Fax: 305-529-0933
Employees: 167
Year Founded: 2002

Price Target and Rating

Average Stock Price Target: $26.43
High Stock Price Target: $34.00
Low Stock Price Target: $23.00
Potential Upside/Downside: +70.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.61
Trailing P/E Ratio: 25.48
Forward P/E Ratio: 8.59
P/E Growth: 0.86
Net Income: $71.41 million
Net Margins: 17.93%
Pretax Margin: 23.73%
Return on Equity: 26.56%
Return on Assets: 22.13%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.88
Quick Ratio: 2.68

Sales & Book Value

Annual Sales: $398.20 million
Price / Sales: 4.61
Cash Flow: $2.06 per share
Price / Cash Flow: 7.56
Book Value: $3.30 per share
Price / Book: 4.71

Miscellaneous

Outstanding Shares: 118,010,000
Free Float: 103,732,000
Market Cap: $1.83 billion
Optionable: Optionable
Beta: 0.89

Social Links

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Patrick J. McEnany (Age 77)
Co-Founder & Chairman
Comp: $1.2M
Mr. Richard John Daly M.B.A. (Age 63)
President, CEO & Director
Comp: $63.12k
Dr. Steven R. Miller Ph.D. (Age 62)
Executive VP, COO & Chief Scientific Officer
Comp: $809.03k
Dr. Gary Ingenito M.D. (Age 68)
Ph.D., Chief Medical & Regulatory Officer
Comp: $751.85k
Mr. Jeffrey Del Carmen (Age 53)
Executive VP & Chief Commercial Officer
Comp: $711.7k
Mr. Michael W. Kalb CPA (Age 53)
Executive VP & CFO
Ms. Mary Coleman
VP & Head of Investor Relations
Mr. Brian Elsbernd J.D. (Age 60)
Chief Compliance Officer & Chief Legal Officer
Comp: $311.42k
Mr. Pete Curry Sr.
Vice President of Sales
Dr. Stanley Iyadurai M.D.
Ph.D., Senior Vice President of Medical Affairs & Drug Discovery

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CPRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Catalyst Pharmaceuticals stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CPRX shares.
View CPRX analyst ratings or view top-rated stocks.
What is Catalyst Pharmaceuticals' stock price target for 2024?: 5 Wall Street analysts have issued 12 month price objectives for Catalyst Pharmaceuticals' stock. Their CPRX share price targets range from $23.00 to $34.00. On average, they anticipate the company's share price to reach $26.43 in the next twelve months. This suggests a possible upside of 72.3% from the stock's current price.
View analysts price targets for CPRX or view top-rated stocks among Wall Street analysts.
How have CPRX shares performed in 2024?: Catalyst Pharmaceuticals' stock was trading at $16.81 at the start of the year. Since then, CPRX shares have decreased by 8.7% and is now trading at $15.34.
View the best growth stocks for 2024 here.
When is Catalyst Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our CPRX earnings forecast.
How were Catalyst Pharmaceuticals' earnings last quarter?: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) posted its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported $0.49 EPS for the quarter, beating analysts' consensus estimates of $0.45 by $0.04. The biopharmaceutical company earned $110.57 million during the quarter, compared to the consensus estimate of $105.78 million. Catalyst Pharmaceuticals had a net margin of 17.93% and a trailing twelve-month return on equity of 26.56%.
What ETFs hold Catalyst Pharmaceuticals' stock?: ETFs with the largest weight of Catalyst Pharmaceuticals (NASDAQ:CPRX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Invesco Biotechnology & Genome ETF (PBE), Janus Henderson Small Cap Growth Alpha ETF (JSML), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), ERShares NextGen Entrepreneurs ETF (ERSX), First Trust Active Factor Small Cap ETF (AFSM) and Hartford Multifactor Small Cap ETF (ROSC).

What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings?: Catalyst Pharmaceuticals updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $455.0 million-$475.0 million, compared to the consensus revenue estimate of $463.2 million.
What other stocks do shareholders of Catalyst Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).
Who are Catalyst Pharmaceuticals' major shareholders?: Catalyst Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.12%), Juncture Wealth Strategies LLC (0.08%), Los Angeles Capital Management LLC (0.07%), Toth Financial Advisory Corp (0.03%), Strategic Advocates LLC (0.01%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Alicia Grande, Brian Elsbernd, Carmen Jeffrey Del, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller.
View institutional ownership trends.
How do I buy shares of Catalyst Pharmaceuticals?: Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CPRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis

Catalyst Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX)

CPRX Stock Price History

CPRX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

CPRX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™